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1  | INTRODUC TION
Cancer remains one of the leading causes of death worldwide. Around 
1.3 million cases of skin cancer (~7% of all cancer cases) were esti-
mated worldwide for 2018, of which about 1 million were non-mel-
anoma skin cancers (NMSC) and nearly 300 000 were melanoma.[1]
pH dysregulation is a hallmark of solid tumors, which further 
drives tumor growth, metastatic potential and immune escape.[2,3] 
The extracellular pH (pHe) of solid tumor cells is more acidic (pHe 6.2-
7.0) as compared to normal cells (pHe 7.2-7.4), while the intracellular 
pH (pHi) of tumor cells (pHi 7.2-7.7) is slightly increased compared 
to normal (pHi 6.9-7.2).
[4,5] This reversed/inside-out pH gradient is 
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Abstract
Solid tumors exhibit an inversed pH gradient with increased intracellular pH (pHi) 
and decreased extracellular pH (pHe). This inside-out pH gradient is generated via 
sodium/hydrogen antiporter 1, vacuolar-type H + ATPases, monocarboxylate trans-
porters, (bi)carbonate (co)transporters and carboanhydrases. Our knowledge on how 
pHe-signals are sensed and what the respective receptors induce inside cells is scarce. 
Some pH-sensitive receptors (GPR4, GPR65/TDAG8, GPR68/OGR1, GPR132/G2A, 
possibly GPR31 and GPR151) and ion channels (acid-sensing ion channels ASICs, 
transient receptor potential vanilloid receptors TRPVs) transduce signals inside cells. 
As little is known on the expression and function of these pH sensors, we used immu-
nostainings to study tissue samples from common and rare skin cancers. Our current 
and future work is directed towards investigating the impact of all the pH-sensing 
receptors in different skin tumors using cell culture techniques with selective knock-
down/knockout (siRNA/CRISPR-Cas9). To study cell migration and proliferation, 
novel impedance-based wound healing assays have been developed and are used. 
The field of pH sensing in tumors and wounds holds great promise for the develop-
ment of pH-targeting therapies, either against pH regulators or sensors to inhibit cell 
proliferation and migration.
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thought to be responsible for some characteristic tumor cell be-
haviour, such as increased proliferation and migration or an altered 
immunological response. For example, in some studies extracellular 
acidification of the tumor environment increased the aggressiveness 
of melanoma cells by promoting their capacity to form metastases.[6]
However, in wounds these processes are important for healing, but 
somehow stopped along the way: sensors that detect changes in pHe 
are potentially involved in feedback mechanisms that stop the neces-
sary proliferation and migration of cells once a wound has healed. The 
striking similarities between wounds and tumors in terms of prolifer-
ation and migration led to Dvorak's description of tumors as wounds 
that do not heal.[7] Drastic changes in pHe are observed during the 
wound healing process of cutaneous lesions. The physiological pHe 
of normal healthy skin lays between 4 and 6, depending on anatomic 
localization and age, and plays an essential role for the homeostasis 
of the cutaneous barrier and regulation of the skin's microbiome.[8,9] 
Significant changes in cutaneous pHe occur when the epithelial barrier 
is disrupted. The pHe on the surface of acute wounds is in the range of 
pH 8.0-8.5 and within two weeks during the wound healing process, 
it gradually decreases to pH 6.0-6.5.[10] In contrast to physiological 
wound healing, chronic wounds exhibit lower pHe at wound margins, 
which negatively influences central processes of wound healing like 
cell proliferation, centripetal cell migration, immune response and ex-
tracellular enzyme activity.[9-11]
The lower pHe of solid tumors is, among others, caused by disor-
ganized vascularization, the development of hypoxic regions, meta-
bolic changes and an altered acid-base regulation[4,5] via the sodium/
hydrogen antiporter (NHE1), the monocarboxylate proton symport-
ers (MCT1, 2 and 4), vacuolar-type H+ ATPases (V-ATPases), anion 
exchangers, (bi)carbonate (co)transporters and different carboanhy-
drases.[6,12] It is the adaption of cancer cells to extracellular acidosis 
that further drives tumor progression.
The cellular responses to dysregulated pHe and pHi are mediated 
by different cellular sensors. Intracellularly, many metabolic enzymes 
and cytoplasmic proteins are described as candidates that mediate 
pHi-sensitive responses.
[5] pHe is likely sensed via cell surface recep-
tors, such as proton-sensitive G-protein-coupled receptors (pH-GP-
CRs), transient receptor potential vanilloid channels (TRPVs) and 
acid-sensing ion channels (ASICs), that mediate the signals from the 
extracellular pH to the cell interior.[13]
Here, we focus on these types of sensors and show how we study 
their expression in skin. We also show concepts on how to analyse their 
impact on cell proliferation and migration in different skin cancers.
2  | PROTON-SENSITIVE GPCRS (PH-
GPCRS) :  WHAT DO THE Y DO IN (SKIN) 
TUMORS?
Proton-sensitive GPCRs (pH-GPCRs) are activated by a decrease 
of pHe via the protonation of different histidine residues on the 
extracellular surface of the receptors.[14] The different pH-GPCRs 
show activation in a range between pH 5 and 8 with individual pH 
sensitivities and G-protein-coupled downstream pathways.[15-17] 
GPR4 (GPR19), GPR65 (TDAG8, T-cell death-associated gene 8), 
GPR68 (OGR1, ovarian cancer GPCR 1) and GPR132 (G2A, G2 accu-
mulation protein) were initially described as receptors for different 
lysolipids,[17] before their sensitivity to changes in extracellular pH 
was demonstrated.[14,18,19] Recently, two more putative pH-GPCRs 
have been described, GPR31 and GPR151, for which studies on their 
physiological role in pH sensing are still rare.[15]
Changes in the expression of certain pH-GPCRs in tumor cells 
may be responsible for establishing an increased tumorigenic poten-
tial, as the pH-GPCRs were shown to play roles in tumor cell pro-
liferation, apoptosis, metastasis, angiogenesis, immune cell function 
and inflammatory processes.[16,20] For example, GPR4, GPR65 and 
GPR132 were found to be often overexpressed in different cancer 
types, including tumors of the breast, ovary, colon, liver and kid-
ney.[21,22] Indeed, ectopic expression of GPR4, GPR65 and GPR132 
has been shown to induce malignant transformation of cultured 
cell lines.[21,23,24] On the other hand, pH-GPCRs such as GPR65 and 
GPR132 are widely expressed by cells of the immune system[16,17] 
and have been associated with tumor-suppressing functions.[25,26] 
Also for GPR68, counteracting effects have been described, de-
pending on whether GPR68 is expressed in the tumor itself or in the 
cells of the host organism. GPR68 seems to function as a tumor-sup-
pressor when expressed in the tumor itself with an inhibitory effect 
on cell migration and metastasis,[27-29] but can have tumor-promoting 
function being expressed in cells of the host organism.[30,31]
Concerning skin cancers, overexpression of GPR4 in squamous 
cell carcinoma has been shown to induce the production of cytokines 
and vascular endothelial growth factor (VEGF) which promoted an-
giogenesis, indicating tumor-promoting activity.[32] Another study 
showed that GPR4 overexpression in B16F10 melanoma cells inhib-
ited acidic pH-induced migration, invasion and metastasis, pointing 
towards tumor-suppressing function.[33] GPR132 was found to be 
upregulated in human epidermal keratinocytes upon UVB radiation 
and H2O2 exposure and to be responsible for mediating lipid-in-
duced cytokine production and cell cycle arrest,[34,35] thereby possi-
bly functioning as sensor for DNA damage and oxidative stress and 
conveying tumor-suppressing activity.
Overall however, little is known about the expression levels and 
role of pH-GPCRs in skin cancers.[20] Therefore, we examined the 
expression profiles of pH-GPCRs in different skin cancers and per-
formed immunohistochemical staining on tissue samples from dif-
ferent skin cancer types. We provided first evidence of pH-GPCR 
expression on the protein level in the selected rare non-melanoma 
skin cancers Merkel cell carcinoma (MCC), dermatofibrosarcoma 
protuberans (DFSP), atypical fibroxanthoma (AFX) and pleomor-
phic dermal sarcoma (PDS) in a previous publication in Experimental 
Dermatology.[36] Different expression patterns in the investigated 
skin cancer types indicate that the different pH-GPCRs may have 
distinct functions in tumor progression. For example, GPR4 and 
GPR65 were not expressed in MCC and also DFSP was negative for 
GPR65. In contrast, AFX and PDS tumors were positive for GPR4 and 
predominantly positive for GPR65. Many skin tumor types showed 
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expression of GPR132, while the expression of GPR68 appears to be 
very heterogeneous.
In our current work, we investigated the expression of pH-GP-
CRs in the non-melanoma cancers squamous cell carcinoma (SCC) 
and basal cell carcinoma (BCC) as well as in malignant melanoma 
(MM) and (compound) naevus cell naevi (NCN). Our tissue mi-
croarray results show that the overall expression of all four GPCRs 
is increased in melanoma when compared to naevus cell naevi. In 
epidermal portions, this observation is even more pronounced (W. 
Klatt, S. Wallner, C. Brochhausen, J. A. Stolwijk, & S. Schreml, un-
published data). These results suggest that an increase in pH-GPCR 
expression in melanoma could be a marker for increased malignancy, 
which requires, however, further investigation.
The identification of characteristic expression patterns of the 
four different pH-GPCRs in different skin cancers may help to con-
tribute to a better therapy. However, a deeper insight into detailed 
pH-GPCR function in tumor development and progression in differ-
ent cell types is needed to address pH-GPCRs as therapeutic targets 
in skin cancer.
3  | A SIC S AND TRPVS: AL SO PH SENSORS 
IN SKIN TUMORS?
Some pH-sensitive ion channels (acid-sensing ion channels ASICs, 
transient receptor potential vanilloid receptors TRPVs) transduce 
signals inside cells.[37] ASICs are non–voltage-gated cation chan-
nels transiently activated by a rapid drop in extracellular pH. 
Protons are the main physiological activators of these channels. 
The ASICs are selective for sodium and belong to the epithelial so-
dium channel (ENaC)/Degenerin family of ion channels.[38] TRPVs 
are non-selective cation channels with high Ca2 + permeability 
representing one out of seven subfamilies of the TRP channel su-
perfamily.[39] The TRPV subfamily can be further subdivided into 
6 isoforms—TRPV1-6. The varied distribution of TRPVs and their 
polymodal activation properties make them ideally suited to a role 
in perceiving and responding to local environmental changes. In 
humans, TRPVs are predominantly involved in sensing tempera-
ture and osmolarity. TRP channels overall have been reported to 
represent possible new targets for diagnosis and chemotherapy 
in cancer.[40] A recent review points out the emerging role of TRP 
channels in cancer progression.[41] The subfamily of TRPV chan-
nels has been mainly correlated with malignant tumor growth and 
progression by regulating cancer cell proliferation, apoptosis, an-
giogenesis, migration and invasion during tumor progression.[42] 
Interestingly, depending on the stage of the cancer, these aspects 
are associated with an increase or decrease in TRPV mRNA and 
protein expression.[43] A member of the TRPA subfamily, namely 
TRPA1, has been demonstrated to be activated by extracellular 
pH.[44] Moreover, TRPM7 channels show an increased channel ac-
tivity as the extracellular pH decreases.[45] The most interesting 
candidates of the ASIC/TRPV ion channel families in terms of skin 
cancer are ASIC1/2 and TRPV1/4.[46-49]
As little is known about the expression and function of these pH 
sensors in tumors, we used immunostainings to study tissue samples 
from common skin tumors. First results from basal cell carcinoma 
(BCC), squamous cell carcinoma (SCC), naevi (NCN) and melanoma 
(MM) are shown (Figure 1). Studies in a larger number of samples will 
now be performed to answer questions regarding expression pro-
files of these pH sensors.
4  | OPEN QUESTIONS AND 
E XPERIMENTAL APPROACH
Expression studies in different skin tumor tissue give an idea of the 
prevalence and local distribution of the putative pH sensors pH-
GPCRs, ASICs and TRPVs. The expression of ASICs and TRPVs has 
not been studied in detail for the various types of skin tumor. It is 
also not known how the levels of expression of pH-GPCRs, TRPVs 
and ASICs influence cancer cell behaviour. Not only pH sensing of 
the tumor cells, but also the pH response of the surrounding tissue 
seems relevant for tumor progression and remains to be investigated. 
Identifying the relevant pH sensors and their influence on tumor 
progression of different tumor types may help to develop individual 
therapeutic strategies. Therefore, we aim at investigating the role of 
these pH sensors in cell migration, proliferation and immune modu-
lation, which are central functions of tumorigenesis. After identify-
ing individual protein levels in different cell types (qPCR, Western 
blot), the next step is to use knockdown (siRNA)/knockout (CRISPR/
Cas9) and overexpression strategies in combination with functional 
cellular assays to answer these questions. The next paragraph de-
scribes a non-invasive, automated assay to study cell migration and 
proliferation, which we use to investigate pH-dependent behaviour 
of skin cancer cells.
5  | MIGR ATION AND PROLIFER ATION IN 
IMPEDANCE-BA SED A SSAYS
In order to study the migration of different cultured skin cancer 
cell types (eg SCC, BCC, melanoma), we use an impedance-based, 
automated wound healing assay (Figure 2). The assay relies on 
growing the cells to confluence on thin gold-film electrodes de-
posited on the bottom of a cell culture dish. Cell coverage of the 
electrodes is monitored by non-invasive impedance readings.[50,51] 
As the adherent cells act like insulating particles and block cur-
rent flow, the impedance gradually increases with increasing cell 
coverage. Though in principle, different electrode dimensions 
and geometries can be used for impedance-based assays, a small 
working electrode in combination with a significantly larger coun-
ter electrode are typically used for wound healing assays.[52] After 
baseline recordings, the cells on the small electrode are killed 
by applying invasive AC currents of 2.4 mA amplitude at 32 kHz 
frequency for 30 s inducing irreversible membrane electropora-
tion (Figure 2A).[53,54] Cell wounding is indicated by a clear drop 
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F I G U R E  1   Immunohistochemistry of 
ASIC1/2 and TRPV1/4: (A) Representative 
samples of the most common skin 
tumors, that is basal cell carcinoma (BCC), 
squamous cell carcinoma (SCC), naevus 
cell naevus (NCN) and melanoma (MM) 
were stained for ASIC1, ASIC2, TRPV1 
or TRPV4, according to the protocol as 
described in Nassios et al[36] and using 
the following primary antibodies: ASIC1: 
PA5-26778, ASIC2: PA5-26222, TRPV1: 
LS-B12677 (Thermo Fisher Scientific Inc, 
Waltham, MA, USA), TRPV4: ab21912 
(abcam, Cambridge, UK). B, Normal skin 
(first row) and control tissues (second to 
fifth row) were stained for ASIC1, ASIC2, 
TRPV1 or TRPV4. Negative (second and 
third row) and positive (fourth and fifth 
row) controls were selected according 
to expression analyses published at 
the human protein atlas (https://www.
prote inatl as.org/). Scale bars: 100 µm. 
Compared to epidermis, BCC showed 
strong expression of the four pH-
sensitive proteins. In contrast, SCC 
showed a quite similar expression of all 
pH-sensitive proteins in comparison to 
normal epidermis, markedly weaker than 
BCC. For NCN and MM, epidermal and 
dermal expression was quite different. 
NCN exhibit strong expression of 
ASIC1/2 in the more superficial portion, 
while the intensity decreases in dermal 
melanocytes. However, TRPV1/4 seems 
to be uniformly expressed even in deeper 
tissue layers. In MM, ASIC1/2 and also 
TRPV1 are also expressed throughout the 
whole tumor. In contrast, TRPV4 staining 
showed only weak expression in MM, 
which may serve to distinguish NCN from 
MM
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in impedance down to values of a cell-free electrode (Figure 2B). 
Cells on the large counter electrode or next to the electrodes 
are not affected by the pulse and migrate onto the electrode 
from the periphery, thereby successively replacing the dead cells 
(Figure 2A). The concomitant impedance recovery reports on the 
time-dependent repopulation of the electrode so that analysis of 
the time course data allows an assessment of cell migration under 
different experimental conditions (Figure 2B).
For example, Figure 2B shows the migration of cultured squa-
mous cell carcinoma cells (SCC111) cells as a function of extracel-
lular pH. The time course of the impedance magnitude (|Z|) has 
been recorded at an AC frequency of 16 kHz for confluent SCC111 
cell layers at four different extracellular pH values before and 
after electrical wounding at time zero. Data represent the mean of 
at least four individual experiments. The impedance magnitude is 
normalized to the last |Z|value before wounding. Immediately after 
wounding and membrane permeabilization, the impedance drops 
to normalized values of 0.3 representing impedance values close 
to the values of cell-free electrodes, as the permeabilized cell bod-
ies no longer restrict current flow. After a short lag phase, the im-
pedance starts to recover at individual rates reporting on the time 
course of cell migration. For pH values close to the physiological 
pH of 7.4 (pH 7.2 & 7.8), the time-dependent impedance recovery 
after electric wounding is very similar and does not indicate any 
pH-dependent impact on cell migration. The prepulse impedance 
values are largely recovered within 16 hours indicating complete 
wound closure. In contrast, a more acidic pH (pH 6.4) led to a 
significantly delayed and incomplete recovery of the impedance. 
Accordingly, the capability of SCC111 cells for collective cell mi-
gration is significantly affected by acidic pH in the extracellular 
environment.
Compared to many other assays used for analysis of cell migra-
tion, the impedance-based assay allows for a time-resolved and au-
tomated data recording and the electrical wounding provides very 
precise wounds that are solely defined by the dimensions of the 
small electrode. As impedance measurements are sensitive to the 
amount of cells that populate the electrode, impedance-based as-
says may also be used to study cell adhesion or cell proliferation as 
a function of different pH conditions.[52] Future studies aim at inves-
tigating the role of pH-sensing proteins using knockdown/knockout 
or overexpressing cell models in these assays.
6  | PERSPEC TIVES
In this article, we focus on the pH-sensitive GPCRs and the ion 
channels ASICs and TRPVs. Other possible interesting pH-sensitive 
“candidates” for further studies in investigating the role in pH sens-
ing in skin tumors are represented by members of the two-pore do-
main (K2P) K+ channel family. Some ion channels of this family—the 
TASK channels (two-pore domain, acid-sensitive K+ channels)—are 
sensitive to changes in extracellular pH in the physiological range, 
making them likely candidates to mediate various pH-dependent 
processes.[37] For TASK-3, high expression levels were reported in 
melanoma cells and channels affected apoptosis and mitochondrial 
function in these cells.[55,56]
F I G U R E  2   Impedance-based migration assay: (A) Live/dead staining of squamous cell carcinoma cells (SCC111, DSMZ) grown onto thin 
gold-film electrodes before wounding, immediately after electric wounding, during wound closure and after migration-based wound healing. 
Cells on the electrodes were stained with the LIVE/DEAD Viability/Cytotoxicity Kit (Thermo Fisher Scientific Inc) and inspected by confocal 
fluorescence microscopy. Viable cells appear green, and nuclei of dead cells are stained red. B, Analysis of pH-dependent migration of 
SCC111 cells grown on gold-film electrodes. Prior to the experiment, the cells were grown to confluence in electrode arrays under normal 
cell culture conditions. After 48 h of preculture, regular medium was replaced by serum-free and (bi)carbonate-free Leibovitz L-15 medium 
adjusted to four different pH values (6.4, 7.2, 7.4 and 7.8), respectively. After 24 h of adaptation to the different pH values at ambient 
CO2 levels, the cells were wounded by the electrical pulses (32 kHz, 2400 µA for 30 s) and the time-dependent impedance recovery was 
recorded. Impedance was normalized to the final value before pulse application. Averaged impedance values immediately prior to wounding 
at time zero were pH 6.4: (9.0 ± 1.2) kΩ, pH 7.2: (9.4 ± 1.2) kΩ, pH 7.4: (9.2 ± 1.8) kΩ and pH 7.8: (9.3 ± 1.4) kΩ. Data represent averages 
with their corresponding standard error (mean ± SE, n ≥ 4) acquired from at least four individual runs. T = 37°C. Impedance data were 
recorded using the ECIS™Zθ system (Applied BioPhysics Inc). Fluorescence micrographs (A) were taken for cells grown on 96-well electrode 
arrays (Type 96W1E+, Applied BioPhysics Inc), while impedance time courses (b) were recorded for the same cells grown on 8-well electrode 
arrays containing a small working electrode (5⋅10-4 cm2) and a much larger counter electrode (A = 0.75 cm2) in each well (Type 8W1E, 
Applied BioPhysics Inc)
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Once relevant pH sensors are identified, targeted strategies 
for clinical settings (antibodies) may be developed that extend the 
few existing approaches to control tumor pH.[20] Since tumors and 
chronic wounds show many parallels, future wound management 
therapies may also benefit from emerging findings.[9,11,20] In addi-
tion to refined in vivo pH-detection technologies, wound dress-
ings with pH-dependent drug release or targeting pH-dependent 
signalling pathways may be developed.[11,57] New wound dress-
ing materials (eg based on nanofibers) with improved capabilities 
for integrated pH sensing and drug release are currently being 
developed.[58,59]
In the long run, a basic understanding of the pH sensing and con-
trol mechanisms in skin tumors and chronic wounds is inevitable for 
improved therapies. The identification of characteristic expression 
patterns of the different pH-sensing proteins in different skin can-
cers and the investigation of their role in proliferation and migration 
may help to contribute to a better therapy.
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